X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (35) 35
humans (32) 32
oncology (27) 27
female (26) 26
multiple myeloma (23) 23
hematology (22) 22
male (21) 21
middle aged (21) 21
aged (17) 17
treatment outcome (13) 13
adult (12) 12
chemotherapy (12) 12
medicine & public health (10) 10
multiple myeloma - pathology (10) 10
analysis (9) 9
survival (9) 9
aged, 80 and over (8) 8
lenalidomide (8) 8
multiple myeloma - drug therapy (8) 8
myeloma (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
bortezomib (7) 7
cancer (7) 7
medicine/public health, general (7) 7
patients (7) 7
retrospective studies (7) 7
trial (7) 7
bone marrow (6) 6
care and treatment (6) 6
expression (6) 6
medical colleges (6) 6
multiple myeloma - diagnosis (6) 6
multiple myeloma - mortality (6) 6
prognosis (6) 6
risk factors (6) 6
therapy (6) 6
adolescent (5) 5
animals (5) 5
austria (5) 5
chemistry (5) 5
dexamethasone (5) 5
disease-free survival (5) 5
hematology, oncology and palliative medicine (5) 5
lymphomas (5) 5
medicine, general & internal (5) 5
transplantation (5) 5
zoledronic acid (5) 5
bendamustine (4) 4
chop (4) 4
combination (4) 4
denosumab (4) 4
development and progression (4) 4
diagnosis (4) 4
diffuse large b-cell lymphoma (4) 4
flow cytometry (4) 4
hemic and lymphatic diseases (4) 4
neoplasm staging (4) 4
remission induction (4) 4
research (4) 4
research paper (4) 4
risk (4) 4
rituximab (4) 4
stem cells (4) 4
survival analysis (4) 4
young adult (4) 4
abridged index medicus (3) 3
after-treatment not covered by subclasses c08b, c08c, c08f,c08g (3) 3
aml (3) 3
angiogenesis (3) 3
angiogenesis inhibitors (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
breast-cancer (3) 3
cancer therapies (3) 3
cell line, tumor (3) 3
cells (3) 3
chemistry, multidisciplinary (3) 3
chronic disease (3) 3
clinical trials (3) 3
compositions based thereon (3) 3
cost-effectiveness (3) 3
cyclophosphamide (3) 3
cyclophosphamide - therapeutic use (3) 3
cytomorphology (3) 3
disease (3) 3
disease progression (3) 3
doxorubicin - therapeutic use (3) 3
durchflusszytometrie (3) 3
follicular lymphoma (3) 3
follow-up studies (3) 3
general processes of compounding (3) 3
guidelines (3) 3
health (3) 3
health care sciences & services (3) 3
hematologic laboratory examination (3) 3
hematopoietic stem cell transplantation (3) 3
in-vivo (3) 3
interdisciplinary collaboration (3) 3
leukemia (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 370 - 381
Journal Article
Annals of Hematology, ISSN 0939-5555, 11/2019, Volume 98, Issue 11, pp. 2569 - 2578
Treatment results for multiple myeloma and plasma cell leukemia have considerably improved, but cure remains elusive and establishing new therapeutic... 
Medicine & Public Health | Hematology | Multiple myeloma | Pixantrone | Plasma cell leukemia | Anti-myeloma activity | Oncology | Drug screening
Journal Article
Journal Article
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 04/2019, Volume 20, Issue 8, p. 1808
Cancer patients frequently use complementary medicine. Curcumin (CUR) and its derivates (from the extract of Curcuma longa L.) represent some of the most... 
cancer treatment | STEM-CELLS | antioxidants | BIOCHEMISTRY & MOLECULAR BIOLOGY | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | CHEMOTHERAPY | DELIVERY | TRIAL | IN-VITRO | PATHWAY | supportive care | IMATINIB | complementary medicine | RESISTANCE | curcumin | anti-inflamation
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e19569 - e19569
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2018, Volume 18, Issue 1, pp. 1008 - 11
Journal Article
memo - Magazine of European Medical Oncology, ISSN 1865-5041, 4/2015, Volume 8, Issue 1, pp. 26 - 29
Achieving a first complete remission in myeloma has become feasible with novel agent-based combination therapies followed by autologous stem cell... 
Consolidation | Bortezomib | Medicine & Public Health | Lenalidomide | Maintenance therapy | Oncology | Medicine/Public Health, general | Multiple Myeloma | Medical colleges | Chemotherapy | Multiple myeloma | Stem cells | Transplantation | Angiogenesis inhibitors | Drug therapy | Thromboembolism | Biological response modifiers | Cancer
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2019, Volume 121, Issue 9, pp. 751 - 757
Background Ixazomib-revlimid-dexamethason showed significant activity in relapsed/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination... 
Therapy | Refractory materials | Dexamethasone | Toxicity | Multiple myeloma | Maintenance | Regression analysis | Thalidomide | Survival | Patients
Journal Article
British journal of haematology, ISSN 0007-1048, 07/2019, Volume 186, Issue 1, pp. 189 - 191
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5732 - 5732
Abstract Introduction Plasma cell leukemia (PCL) is a leukemic variant of Myeloma arising either de novo or from clinically pre-existent Multiple Myeloma (MM).... 
Journal Article